Medical/Pharmaceuticals
Zuellig Pharma Selects CYFIRMA to Elevate Cyber-intelligence Capabilities and Strengthen Cybersecurity Posture
SINGAPORE, June 25, 2021 /PRNewswire/ -- CYFIRMA, a threat discovery and
cyber-intelligence platform company, funded by Goldman Sachs, Zodius Capital
and Z3Partners, today announced thatZuellig Pharma
2021-06-25 12:57
2453
GenScript receives "Best Contract Development and Manufacturing Organization Award" in the Korea Bioprocessing Excellence Awards 2021
SINGAPORE, June 25, 2021 /PRNewswire/ -- GenScript receives the "Best Contract
Development and Manufacturing Organization Award" on the Korea Bioprocessing
Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO
award for two years in a row.
2021-06-25 10:30
19085
Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
2021-06-25 09:01
23031
Moving ahead: Copan announces a major rebranding and launches a new website
BRESCIA, Italy, June 25, 2021 /PRNewswire/ -- Time of change for Copan. The Italian preanalytics company announced the completion of an extensive rebranding initiative which includes a new logo and a new website with updated functionalities. The rebranding aims to represent at best the company va...
2021-06-25 08:25
3491
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-06-25 08:00
6973
Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management
- Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collaborative database solution - CDD provides a secure research database platform enabling seamless collaboration between drug discovery and development teams that are in different...
2021-06-25 05:57
2585
Peijia Medical's Jasper® SS Detachable Coil Receives NMPA Approval for Commercialization
SUZHOU, China, June 24, 2021 /PRNewswire/ -- On June 15, 2021, Jasper® SS—a new detachable coil independently developed by Achieva Medical, subsidiary of Peijia Medical (9996.HK)—was approved by the National Medical Products Administration ("NMPA") for commercialization (registration number GXZZ ...
2021-06-25 00:27
17064
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from S...
2021-06-25 00:26
3792
GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems
Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND, June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided The...
2021-06-24 22:33
14645
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from Shan...
2021-06-24 20:43
3183
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat (also known as Chidamide, Epidaza ®, HBI-8000) monotherapy of relapsed or refractory (R/R) adult T-cell le...
2021-06-24 19:00
3551
Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness® VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds
This new clinical trial is being conducted through their partnership with Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent company China National Biotec Group Co., LTD (CNBG) and will be used to seek marketing approval inChina BROOKLINE, Mass., June 24, 2021 /PRNewswire/ -- Ad...
2021-06-24 18:00
2837
Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics
BOSTON, June 24, 2021 /PRNewswire/ -- Luye Pharma Group's subsidiary Boan
Biotech recently published research results for its innovative in-house
bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) inAntibody
Therapeutics.
2021-06-24 14:49
4000
China's first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)
* The first* CAR-T cell therapy approved by NMPA: opening a new era of cell therapy inChina * Individualized living-cell-based medicine: genetically modify patient's T-cells to expresses a chimeric antigen receptor (CAR) that will activate T-cells upon engaging cells carrying the specific ant...
2021-06-24 14:46
2696
CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application
* Key efficacy data showed that GAVRETO demonstrated deep and durable clinical activity in Chinese patients with RET fusion-positive non-small cell lung cancer (NSCLC) * CStone plans to submit new indication application to the China National Medical Products Administration for GAVRETO as a fi...
2021-06-24 08:05
7295
Endurance RP Limited: A New Name, A New Perspective Eye on China's fertility and longevity market
HONG KONG, June 23, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce the official completion of the rebranding of the Group, with the Company name changed to "Endurance RP...
2021-06-23 22:33
16239
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights: * Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. * Concurrence with Alterity's plan to target early stage MSA patients. * Endorsement on selection ...
2021-06-23 21:21
15395
Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections
* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...
2021-06-23 19:28
1763
IMPRESSION - A randomised trial to evaluate the efficacy of MagicTouch Sirolimus Coated Balloon in Dysfunctional Fistula progresses rapidly
SINGAPORE, June 23, 2021 /PRNewswire/ -- Concept Medical Inc.,
2021-06-23 19:02
3178
Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment
TAIPEI and SAN DIEGO, June 23, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for the treatment of cancer, rare conditions, and novel coronaviruses, today announced that it has submitted an I...
2021-06-23 19:00
1805
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 317 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 256 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 250 media titles]
2026-02-16 08:00Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
8535
The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
2026-02-14 13:00
6734
U Power to Present at OTC Markets AI & Technology Investor Conference on February 19
2026-02-14 01:00
6601